We are live on ! Find out more
THRX

Theseus Pharmaceuticals, Inc. Common Stock
THRX

Delisted

THRX was delisted on the 13th of February, 2024.

Back to rankings

1 hedge funds and large institutions have $0 invested in Theseus Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 70 → 1 (-69)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $146M → $0 (-$146M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 69

Holders
1
Holders Change
-69
Holders Change %
-98.57%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
69
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$53.8K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$71.7M
2
FCMV
Foresite Capital Management V
California
-$16.6M
3
TCM
Tang Capital Management
California
-$13.2M
4
FLSM
Frazier Life Sciences Management
California
-$8.58M
5
BlackRock
BlackRock
New York
-$5.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
51
American International Group
New York
– -$40.7K -10,060 Closed
New York State Common Retirement Fund
52
New York State Common Retirement Fund
New York
– -$38.7K -9,564 Closed
A
53
AJOVista
Massachusetts
– -$38.6K -9,520 Closed
TRCT
54
Tower Research Capital (TRC)
New York
– -$37.7K -9,302 Closed
Wells Fargo
55
Wells Fargo
California
– -$25.2K -6,211 Closed
Osaic Holdings
56
Osaic Holdings
Arizona
– -$24.5K -6,043 Closed
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
– -$22K -5,615 Closed
California State Teachers Retirement System (CalSTRS)
58
California State Teachers Retirement System (CalSTRS)
California
– -$13.5K -3,331 Closed
Citigroup
59
Citigroup
New York
– -$11.6K -2,876 Closed
Fidelity Investments
60
Fidelity Investments
Massachusetts
– -$7.91K -1,953 Closed
Legal & General Group
61
Legal & General Group
United Kingdom
– -$7.82K -1,930 Closed
AB
62
Amalgamated Bank
New York
– -$7K -1,612 Closed
PNC Financial Services Group
63
PNC Financial Services Group
Pennsylvania
– -$3.71K -917 Closed
AIP
64
Ameritas Investment Partners
Nebraska
– -$3.6K -889 Closed
BTI
65
Blue Trust Inc
Georgia
– -$1K -278 Closed
EWA
66
EverSource Wealth Advisors
Alabama
– -$1.08K -267 Closed
GWS
67
Glassman Wealth Services
Virginia
– -$976 -241 Closed
Russell Investments Group
68
Russell Investments Group
United Kingdom
– -$255 -63 Closed
FFA
69
Farther Finance Advisors
California
– -$89 -22 Closed
Goldman Sachs
70
Goldman Sachs
New York
– +$53.8K +13,384 +79%
1 2
3

THRX Hedge Fund Activity: Q1 2024 in Review

1 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q1 2024, worth a combined $0 — down 100% from $146M a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of THRX and 0 opened new positions — a net loss of 69 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Goldman Sachs, adding an estimated $53.8K. The largest seller was OrbiMed, exiting entirely with an estimated $71.7M sold.

  • 1 institutional investor held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q1 2024, down from 70 in Q4 2023.
  • Funds reported $0 of Theseus Pharmaceuticals, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 69 closed out, a net change of -69 holders.
  • The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Goldman Sachs, an estimated $53.8K added.
  • The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was OrbiMed, an estimated $71.7M sold.

Based on aggregated 13F filings for Q1 2024.